This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Douglas J. Onorato
New London, Conn

Mr Onorato is a fourth-year medical student at the University of Connecticut, Farmington.

Arch Ophthalmol. 1985;103(9):1274-1276.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—In the January issue of the ARCHIVES, Schwartz and Sher¹ describe an asthmatic patient who experienced respiratory distress after being treated with an ophthalmic solution of dipivefrin hydrochloride containing 0.1% sodium metabisulfite.

Sulfiting agent is a generic term used to describe any of a group of similar sulfur-containing chemicals employed as preservatives and antioxidants in the restaurant, fermentation, packaged food, and pharmaceutical industries. Six sulfiting agents have been listed by the Food and Drug Administration (FDA) as generally regarded as safe (GRAS) substances: sulfur dioxide, sodium sulfite, sodium and potassium bisulfite, and sodium and potassium metabisulfite. Under FDA regulation, labeling requirements for GRAS substances are not as inclusive as they are for other, more controlled substances.² Currently, the GRAS status of these six agents is under review.

Suspected adverse reactions to sulfiting agents have received increased attention in both the lay and medical literature. Those . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?